{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T03:13:11Z","timestamp":1780715591129,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2010,6,11]],"date-time":"2010-06-11T00:00:00Z","timestamp":1276214400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s10067-010-1486-3","type":"journal-article","created":{"date-parts":[[2010,6,10]],"date-time":"2010-06-10T03:56:58Z","timestamp":1276142218000},"page":"1079-1084","source":"Crossref","is-referenced-by-count":33,"title":["The role of zoledronic acid in the management of osteoporosis"],"prefix":"10.1007","volume":"29","author":[{"given":"Michael","family":"Maricic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,11]]},"reference":[{"key":"1486_CR1","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s00198-006-0179-x","volume":"17","author":"D Weycker","year":"2006","unstructured":"Weycker D, Macarios D, Edelsberg J, Oster G (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17:1645\u20131652","journal-title":"Osteoporos Int"},{"key":"1486_CR2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00002512-200724010-00003","volume":"24","author":"A Papaioannou","year":"2007","unstructured":"Papaioannou A, Kennedy CC, Dolovich L, Lau E, Adachi JD (2007) Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging 24:37\u201355","journal-title":"Drugs Aging"},{"key":"1486_CR3","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","volume":"81","author":"ES Siris","year":"2006","unstructured":"Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013\u20131022","journal-title":"Mayo Clin Proc"},{"key":"1486_CR4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0002-9343(03)00362-0","volume":"115","author":"AN Tosteson","year":"2003","unstructured":"Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM et al (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209\u2013216","journal-title":"Am J Med"},{"key":"1486_CR5","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T (2005) Adherence to medications. N Engl J Med 353:487\u2013497","journal-title":"N Engl J Med"},{"key":"1486_CR6","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00198-003-1502-4","volume":"14","author":"RA Yood","year":"2003","unstructured":"Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965\u2013968","journal-title":"Osteoporos Int"},{"key":"1486_CR7","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00198-004-1652-z","volume":"15","author":"JJ Caro","year":"2004","unstructured":"Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003\u20131008","journal-title":"Osteoporos Int"},{"key":"1486_CR8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","volume":"296","author":"JF Dunford","year":"2001","unstructured":"Dunford JF, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD et al (2001) Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235\u2013242","journal-title":"J Pharmacol Exp Ther"},{"key":"1486_CR9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/ddr.10071","volume":"55","author":"JR Green","year":"2002","unstructured":"Green JR, Rogers MJ (2002) Pharmacological profile of zoledronic acid: a highly potent inhibitor of bone resorption. Drug Dev Res 55:210\u2013224","journal-title":"Drug Dev Res"},{"key":"1486_CR10","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"1486_CR11","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Col\u00f3n-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799\u20131809","journal-title":"N Engl J Med"},{"key":"1486_CR12","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","volume":"373","author":"DM Reid","year":"2009","unstructured":"Reid DM, Devogelaer J-P, Saag K, Roux C, Lau C-S, Reginster J-Y et al (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy randomised controlled trial. Lancet 373:1253\u20131263","journal-title":"Lancet"},{"key":"1486_CR13","unstructured":"Orwoll E, Miller P, Adachi J, Brown J, Adler R, Kendler D et al (2009) Once-yearly I.V. zoledronic acid 5\u00a0mg versus weekly oral alendronate 70\u00a0mg in men with osteoporosis. Presented at: 91st Annual Meeting of the Endocrine Society (ENDO); June 10-13, Washington DC, USA"},{"key":"1486_CR14","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/AOG.0b013e3181bdce0a","volume":"114","author":"M McClung","year":"2009","unstructured":"McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou C-L (2009) Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass. Obstet Gynecol 114:999\u20131007","journal-title":"Obstet Gynecol"},{"key":"1486_CR15","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","volume":"346","author":"IR Reid","year":"2002","unstructured":"Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U et al (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653\u2013661","journal-title":"N Engl J Med"},{"key":"1486_CR16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2007.03.011","volume":"41","author":"M McClung","year":"2007","unstructured":"McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A et al (2007) Intravenous zoledronic acid 5\u00a0mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 41:122\u2013128","journal-title":"Bone"},{"key":"1486_CR17","unstructured":"Reclast [package insert] (2008) East Hanover, NJ: Novartis Pharmaceuticals Corporation"},{"key":"1486_CR18","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","volume":"22","author":"S Khosla","year":"2007","unstructured":"Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479\u20131491","journal-title":"J Bone Miner Res"},{"key":"1486_CR19","first-page":"3078","volume":"103","author":"D Felsenberg","year":"2006","unstructured":"Felsenberg D, Hoffmeister B, Amling M, Mundlos S, Seibel MJ, Fratzl P (2006) Kiefernekrosen nach hoch dosierter Bisphosphonattherapie. Deutsches \u00c4rzteblatt 103:3078\u20133081","journal-title":"Deutsches \u00c4rzteblatt"},{"key":"1486_CR20","first-page":"801","volume":"35","author":"P Sambrook","year":"2006","unstructured":"Sambrook P, Olver I, Goss A (2006) Bisphosphonates and osteonecrosis of the jaw. Aust Fam Phys 35:801\u2013803","journal-title":"Aust Fam Phys"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-010-1486-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-010-1486-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-010-1486-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:28:58Z","timestamp":1740173338000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-010-1486-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,11]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["1486"],"URL":"https:\/\/doi.org\/10.1007\/s10067-010-1486-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,11]]}}}